Evidence map›Paper›PMID 35162109›Full record

ArticleInternational journal of environmental research and public health2022

Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.

Roger T Buju, Pierre Z Akilimali, Erick N Kamangu, Gauthier K Mesia, Jean Marie N Kayembe, Hippolyte N Situakibanza

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Observational
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Roger T BujuDepartment of Public Health, Faculté de Medicine, University of Bunia, Bunia P.O. Box 292, Congo.
Pierre Z AkilimaliDepartment of Biostatistics and Epidemiology, Kinshasa School of Public Health, University of Kinshasa, Kinshasa P.O. Box 11850, Congo.
Erick N KamanguDépartement des Sciences de Base, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Congo.
Gauthier K MesiaDépartement de Pharmacologie Clinique, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Congo.ORCID 0000-0002-2406-2631
Jean Marie N KayembeDepartment Internal Medicine, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Congo.
Hippolyte N SituakibanzaDepartment of Tropical Medicine and Infectious Disease, School of Medicine, University of Kinshasa, Kinshasa P.O. Box 11850, Congo.
University of Kinshasa · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Democratic Republic of the Congo adopted the integrase inhibitor dolutegravir (DTG) as part of its preferred first-line HIV treatment regimen in 2019. This study aimed to identify predictors of viral non-suppression among HIV-infected patients under a DTG-based regimen in the context of ongoing armed conflict since 2017 in the city of Bunia in the DRC. We conducted a cohort study of 468 patients living with HIV under DTG in all health facilities in Bunia. We calculated the proportion of participants with an HIV RNA of below 50 copies per milliliter. About three in four patients (72.8%) in this cohort had a viral load (VL) of <50 copies/mL after 6-12 months. After controlling for the effect of other covariates, the likelihood of having non-suppression remained significantly lower among the 25-34 age group and self-reported naïve patients with a baseline VL of ≥50 copies/mL. The likelihood of having non-suppression remained significantly higher among those who were at advanced stages of the disease, those with abnormal serum creatinine, those with high baseline HIV viremia over 1000 copies/mL, and the Sudanese ethnic group compared to the reference groups. This study suggests that we should better evaluate adherence, especially among adolescents and economically vulnerable populations, such as the Sudanese ethnic group in the city of Bunia. This suggests that an awareness of the potential effects of DTG and tenofovir is important for providers who take care of HIV-positive patients using antiretroviral therapy (ART), especially those with abnormal serum creatinine levels before starting treatment.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAdolescentCohort StudiesDemocratic Republic of the CongoDolutegravirHeterocyclic Compounds, 3-RingHumansOxazinesPiperazinesProspective StudiesPyridonesViral LoadAnti-HIV AgentsDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesBuniaconflict settingdolutegravirvirologic failure

Identifiers

PMID35162109
PMCPMC8834045
OpenAlexW4206273165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.